Charles River Laboratories International, Inc.

NYSE:CRL

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 7.38 B

Share Price

USD 150.21

Avg Daily Volume

1,622,587

Change (1 day)

1.22%

Change (1 year)

-27.22%

Change (YTD)

-18.63%

Charles River Laboratories International, Inc. Revenue for the Trailing 12 Months (TTM) ending March 29, 2025: USD 4.02 B

Charles River Laboratories International, Inc. Revenue is USD 4.02 B for the Trailing 12 Months (TTM) ending March 29, 2025, a -2.16% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Charles River Laboratories International, Inc. Revenue for the Trailing 12 Months (TTM) ending March 30, 2024 was USD 4.11 B, a 0.49% change year over year.
Charles River Laboratories International, Inc. Revenue for the Trailing 12 Months (TTM) ending April 01, 2023 was USD 4.09 B, a 12.73% change year over year.
Charles River Laboratories International, Inc. Revenue for the Trailing 12 Months (TTM) ending March 26, 2022 was USD 3.63 B, a 19.34% change year over year.
Charles River Laboratories International, Inc. Revenue for the Trailing 12 Months (TTM) ending March 27, 2021 was USD 3.04 B, a 11.67% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

NYSE: CRL

Charles River Laboratories International, Inc.

CEO	Mr. James C. Foster J.D.
IPO Date	June 23, 2000
Location	United States
Headquarters	251 Ballardvale Street
Employees	18,700
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.